BRY10

BRY10 is a discontinued bispecific monoclonal antibody developed by Chugai Pharmaceutical for the treatment of multiple myeloma. It was engineered as a T-cell engager using Chugai's proprietary ART-Ig (Asymmetric Recombinant Technology - Immunoglobulin) platform, which allows for the efficient production of asymmetric bispecific antibodies. The molecule was designed to simultaneously bind to B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells, and the CD3 epsilon subunit of the T-cell receptor complex on T-lymphocytes. This dual binding mechanism was intended to facilitate the recruitment and activation of cytotoxic T-cells to specifically target and eliminate BCMA-expressing myeloma cells. BRY10 entered Phase 1 clinical trials, but development was subsequently halted, likely in favor of other BCMA-targeted candidates within the Roche Group pipeline, such as cevostamab.